<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00995904</url>
  </required_header>
  <id_info>
    <org_study_id>MAP0020-CL-P201</org_study_id>
    <nct_id>NCT00995904</nct_id>
  </id_info>
  <brief_title>Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma</brief_title>
  <official_title>A Randomized, Open-Label, 3-Dose, 3-Period, Crossover Phase 2 Study Investigating the Tolerability and Pharmacokinetics of MAP0010 in Children 4 Through 11 Years Old With a History of Mild-To-Moderate Stable Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 study was to investigate the tolerability of unit dose budesonide (MAP0020) at
      three doses in pediatric volunteers with a diagnosis and history of mild-to-moderate stable
      asthma and evaluate the pharmacokinetic profile of budesonide resulting from inhalation
      aerosol delivery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Budesonide After Administration of MAP0020</measure>
    <time_frame>12 hours</time_frame>
    <description>The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf) of Budesonide After Administration of MAP0020</measure>
    <time_frame>12 hours</time_frame>
    <description>The AUC(0-inf) is the area under the plot of plasma concentration of drug to time infinity after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg*min/ml).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t1/2) of Budesonide After Administration of MAP0020</measure>
    <time_frame>12 hours</time_frame>
    <description>Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Treatment A, then Treatment B, then Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment A, then Treatment C, then Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B, then Treatment A, then Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B, then Treatment C, then Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C, then Treatment A, then Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study visits were separated by 3-7 day intervals.
Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C, then Treatment B, then Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study visits were separated by 3-7 day intervals. Treatment C: 21ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 2; Treatment B: 42ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>84ug MAP0020</intervention_name>
    <description>84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol</description>
    <arm_group_label>Treatment A, then Treatment B, then Treatment C</arm_group_label>
    <arm_group_label>Treatment A, then Treatment C, then Treatment B</arm_group_label>
    <arm_group_label>Treatment B, then Treatment A, then Treatment C</arm_group_label>
    <arm_group_label>Treatment B, then Treatment C, then Treatment A</arm_group_label>
    <arm_group_label>Treatment C, then Treatment A, then Treatment B</arm_group_label>
    <arm_group_label>Treatment C, then Treatment B, then Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>42ug MAP0020</intervention_name>
    <description>42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol</description>
    <arm_group_label>Treatment A, then Treatment B, then Treatment C</arm_group_label>
    <arm_group_label>Treatment A, then Treatment C, then Treatment B</arm_group_label>
    <arm_group_label>Treatment B, then Treatment A, then Treatment C</arm_group_label>
    <arm_group_label>Treatment B, then Treatment C, then Treatment A</arm_group_label>
    <arm_group_label>Treatment C, then Treatment A, then Treatment B</arm_group_label>
    <arm_group_label>Treatment C, then Treatment B, then Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>21ug MAP0020</intervention_name>
    <description>21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol</description>
    <arm_group_label>Treatment A, then Treatment B, then Treatment C</arm_group_label>
    <arm_group_label>Treatment A, then Treatment C, then Treatment B</arm_group_label>
    <arm_group_label>Treatment B, then Treatment A, then Treatment C</arm_group_label>
    <arm_group_label>Treatment B, then Treatment C, then Treatment A</arm_group_label>
    <arm_group_label>Treatment C, then Treatment A, then Treatment B</arm_group_label>
    <arm_group_label>Treatment C, then Treatment B, then Treatment A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male or female children with a documented diagnosis of mild-to-moderate persistent
             asthma (according to the 2007 NIH [EPR] criteria) for at least 1 year prior to
             screening and medically stable for a minimum of 6 months prior to screening.

          2. Children 4 through 11 years old (up to one day prior to their 12th birthday at
             randomization).

          3. Body weight &gt;=45 lbs, body mass index (BMI) &lt;=30 kg/m2

          4. ICS users had to have been taking an ICS for &gt;=3 months and on a stable dose for &gt;= 1
             month before Visit 1.ICS users had to be stable enough and able to withhold their
             therapeutic ICS for 24 hours prior to study drug administration,

          5. Subjects already on stable immunotherapy (ie, allergy shots)if not anticipated to
             change during the study.

        Key Exclusion Criteria:

          1. Females of child-bearing potential/menarche.

          2. Diagnosis of any other significant chronic illness or abnormality.

          3. Use of corticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Ratner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sylvana Research Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ammar Hatab, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Coast Clinical Trials LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Coast Clinical Trials LLC</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvana Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2009</study_first_submitted>
  <study_first_submitted_qc>October 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2009</study_first_posted>
  <results_first_submitted>April 17, 2013</results_first_submitted>
  <results_first_submitted_qc>October 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2013</results_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthmatic children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This is a 3-treatment, 3-period, 6-sequence crossover study. Each subject received all 3 treatments in a randomly assigned order: treatments A, B, and C, the sequences were ABC, ACB, BAC, BCA, CAB, and CBA.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment A, Then Treatment B, Then Treatment C</title>
          <description>Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4</description>
        </group>
        <group group_id="P2">
          <title>Treatment A, Then Treatment C, Then Treatment B</title>
          <description>Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4</description>
        </group>
        <group group_id="P3">
          <title>Treatment B, Then Treatment A, Then Treatment C</title>
          <description>Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4</description>
        </group>
        <group group_id="P4">
          <title>Treatment B, Then Treatment C, Then Treatment A</title>
          <description>Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4</description>
        </group>
        <group group_id="P5">
          <title>Treatment C, Then Treatment A, Then Treatment B</title>
          <description>Study visits were separated by 3-7 day intervals. Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4</description>
        </group>
        <group group_id="P6">
          <title>Treatment C, Then Treatment B, Then Treatment A</title>
          <description>Study visits were separated by 3-7 day intervals. Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Visit 2 (Randomization)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Visit 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="3">One subject was withdrawn from the study after completion of Visit 2 but prior to Visit 3.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Visit 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-up Visit (Final Visit)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>All patients that were enrolled in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Budesonide After Administration of MAP0020</title>
        <description>The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).</description>
        <time_frame>12 hours</time_frame>
        <population>Patients with available data at specified time points are included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>21ug MAP0020</title>
            <description>21ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) as per protocol</description>
          </group>
          <group group_id="O2">
            <title>42ug MAP0020</title>
            <description>42ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) as per protocol</description>
          </group>
          <group group_id="O3">
            <title>84ug MAP0020</title>
            <description>84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) as per protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Budesonide After Administration of MAP0020</title>
          <description>The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).</description>
          <population>Patients with available data at specified time points are included in the analysis population.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" spread="72.9"/>
                    <measurement group_id="O2" value="175" spread="96.0"/>
                    <measurement group_id="O3" value="370" spread="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-inf) of Budesonide After Administration of MAP0020</title>
        <description>The AUC(0-inf) is the area under the plot of plasma concentration of drug to time infinity after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg*min/ml).</description>
        <time_frame>12 hours</time_frame>
        <population>Patients with available data at specified time points are included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>21ug MAP0020</title>
            <description>21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol</description>
          </group>
          <group group_id="O2">
            <title>42ug MAP0020</title>
            <description>42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol</description>
          </group>
          <group group_id="O3">
            <title>84ug MAP0020</title>
            <description>84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-inf) of Budesonide After Administration of MAP0020</title>
          <description>The AUC(0-inf) is the area under the plot of plasma concentration of drug to time infinity after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg*min/ml).</description>
          <population>Patients with available data at specified time points are included in the analysis population.</population>
          <units>pg*min/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3750" spread="1560"/>
                    <measurement group_id="O2" value="8710" spread="3270"/>
                    <measurement group_id="O3" value="19400" spread="8230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-life (t1/2) of Budesonide After Administration of MAP0020</title>
        <description>Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.</description>
        <time_frame>12 hours</time_frame>
        <population>Patients with available data at specified time points are included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>21ug MAP0020</title>
            <description>21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol</description>
          </group>
          <group group_id="O2">
            <title>42ug MAP0020</title>
            <description>42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol</description>
          </group>
          <group group_id="O3">
            <title>84ug MAP0020</title>
            <description>84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (t1/2) of Budesonide After Administration of MAP0020</title>
          <description>Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.</description>
          <population>Patients with available data at specified time points are included in the analysis population.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" spread="31.2"/>
                    <measurement group_id="O2" value="74.6" spread="29.8"/>
                    <measurement group_id="O3" value="86.9" spread="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All 25 subjects who received 21ug MAP0020, 24 subjects who received 42ug MAP0020, and 24 subjects who received 84ug MAP0020 are included in the adverse event analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>21ug MAP0020</title>
          <description>21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol</description>
        </group>
        <group group_id="E2">
          <title>42ug MAP0020</title>
          <description>42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol</description>
        </group>
        <group group_id="E3">
          <title>84ug MAP0020</title>
          <description>84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP, Scientific Affairs</name_or_title>
      <organization>MAP Pharmaceuticals Inc., a wholly owned subsidiary of Allergan</organization>
      <phone>650-386-3100</phone>
      <email>dkellerman@mappharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

